$DNTH
Dianthus Therapeutics, Inc. /DE/

2022 Form 8-K Financial Statement

#000119312523301206 Filed on December 21, 2023

View on sec.gov

Income Statement

Concept 2022 2021 Q4 2021
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $25.76M $7.026M $27.93M
YoY Change -7.75% 3.17% -0.58%
% of Gross Profit
Research & Development $55.14M $13.11M $46.77M
YoY Change 17.91% 6.97% -7.61%
% of Gross Profit
Depreciation & Amortization $1.900M $535.0K $2.020M
YoY Change -5.94% 7.0% 2.02%
% of Gross Profit
Operating Expenses $80.90M $20.14M $74.69M
YoY Change 8.31% 5.61% -5.09%
Operating Profit -$80.90M -$74.69M
YoY Change 8.31%
Interest Expense $4.440M $848.0K $3.556M
YoY Change 24.86% -5.78% -5.68%
% of Operating Profit
Other Income/Expense, Net $1.229M -$23.00K
YoY Change -5443.48%
Pretax Income -$76.46M -$19.29M -$71.14M
YoY Change 7.49% 6.18% -5.08%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$76.50M -$19.29M -$71.10M
YoY Change 7.59% 6.18% -5.12%
Net Earnings / Revenue
Basic Earnings Per Share -$1.29 -$1.29
Diluted Earnings Per Share -$1.29 -$327.9K -$1.295M
COMMON SHARES
Basic Shares Outstanding 59.37M 54.95M
Diluted Shares Outstanding 59.37M 54.95M

Balance Sheet

Concept 2022 2021 Q4 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $112.0M $176.9M $176.9M
YoY Change -36.67% 18.9% 18.9%
Cash & Equivalents $57.63M $131.7M $131.7M
Short-Term Investments $54.42M $45.28M $45.28M
Other Short-Term Assets $3.561M $3.767M $3.767M
YoY Change -5.47% 39.52% 39.52%
Inventory
Prepaid Expenses
Receivables $469.0K
Other Receivables
Total Short-Term Assets $115.6M $180.7M $180.7M
YoY Change -36.02% 19.27% 19.27%
LONG-TERM ASSETS
Property, Plant & Equipment $29.26M $7.461M $7.461M
YoY Change 292.21% -10.11% -10.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.780M $1.780M $1.780M
YoY Change 0.0% -1.11% -1.11%
Total Long-Term Assets $31.04M $9.241M $9.241M
YoY Change 235.93% -8.5% -8.5%
TOTAL ASSETS
Total Short-Term Assets $115.6M $180.7M $180.7M
Total Long-Term Assets $31.04M $9.241M $9.241M
Total Assets $146.6M $189.9M $189.9M
YoY Change -22.79% 17.53% 17.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.454M $3.040M $3.040M
YoY Change -19.28% -20.0% -20.0%
Accrued Expenses $12.10M $7.823M $7.268M
YoY Change 66.41% 10.18% 2.37%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.55M $10.86M $10.86M
YoY Change 33.93% -4.71% -4.71%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $26.14M $6.399M $6.399M
YoY Change 308.47% 1.57% 1.57%
Total Long-Term Liabilities $26.14M $6.399M $6.399M
YoY Change 308.47% 1.57% 1.57%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.55M $10.86M $10.86M
Total Long-Term Liabilities $26.14M $6.399M $6.399M
Total Liabilities $40.69M $17.26M $17.26M
YoY Change 135.7% -2.47% -2.47%
SHAREHOLDERS EQUITY
Retained Earnings -$325.6M
YoY Change
Common Stock $498.3M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $106.0M $172.7M $172.7M
YoY Change
Total Liabilities & Shareholders Equity $146.6M $189.9M $189.9M
YoY Change -22.79% 17.53% 17.53%

Cashflow Statement

Concept 2022 2021 Q4 2021
OPERATING ACTIVITIES
Net Income -$76.50M -$19.29M -$71.10M
YoY Change 7.59% 6.18% -5.12%
Depreciation, Depletion And Amortization $1.900M $535.0K $2.020M
YoY Change -5.94% 7.0% 2.02%
Cash From Operating Activities -$67.09M -$15.69M -$59.53M
YoY Change 12.7% 14.28% -7.01%
INVESTING ACTIVITIES
Capital Expenditures $314.0K -$15.00K -$1.264M
YoY Change -124.84% -92.86% 216.0%
Acquisitions
YoY Change
Other Investing Activities -$9.498M -$10.31M $44.69M
YoY Change -121.25% -85.43% -536.45%
Cash From Investing Activities -$9.812M -$10.32M $43.43M
YoY Change -122.59% -85.46% -508.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.904M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.878M 124.0K 89.60M
YoY Change -96.79% -89.49% 32.27%
NET CHANGE
Cash From Operating Activities -67.09M -15.69M -59.53M
Cash From Investing Activities -9.812M -10.32M 43.43M
Cash From Financing Activities 2.878M 124.0K 89.60M
Net Change In Cash -74.02M -25.89M 73.50M
YoY Change -200.72% -69.01% -1162.11%
FREE CASH FLOW
Cash From Operating Activities -$67.09M -$15.69M -$59.53M
Capital Expenditures $314.0K -$15.00K -$1.264M
Free Cash Flow -$67.40M -$15.67M -$58.27M
YoY Change 15.68% 15.94% -8.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001690585
CY2023Q4 dei Document Type
DocumentType
8-K
CY2023Q4 dei Document Period End Date
DocumentPeriodEndDate
2023-12-21
CY2023Q4 dei Entity Registrant Name
EntityRegistrantName
DIANTHUS THERAPEUTICS, INC.
CY2023Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q4 dei Entity File Number
EntityFileNumber
001-38541
CY2023Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-0724163
CY2023Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
7 Times Square
CY2023Q4 dei Entity Address Address Line2
EntityAddressAddressLine2
43rd Floor
CY2023Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2023Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
CY2023Q4 dei City Area Code
CityAreaCode
929
CY2023Q4 dei Local Phone Number
LocalPhoneNumber
999-4055
CY2023Q4 dei Written Communications
WrittenCommunications
false
CY2023Q4 dei Soliciting Material
SolicitingMaterial
false
CY2023Q4 dei Pre Commencement Tender Offer
PreCommencementTenderOffer
false
CY2023Q4 dei Pre Commencement Issuer Tender Offer
PreCommencementIssuerTenderOffer
false
CY2023Q4 dei Security12b Title
Security12bTitle
Common Stock, $0.001 Par Value
CY2023Q4 dei Trading Symbol
TradingSymbol
DNTH
CY2023Q4 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q4 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0625
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15365000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7638000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
60125000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
0
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4700000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
469000
CY2022Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
938000
CY2021Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
1007000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
905000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
274000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
82033000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
9388000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
142000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
814000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2022Q4 dnth Other Assets And Restricted Cash
OtherAssetsAndRestrictedCash
121000
CY2021Q4 dnth Other Assets And Restricted Cash
OtherAssetsAndRestrictedCash
30000
CY2022Q4 us-gaap Assets
Assets
83110000
CY2021Q4 us-gaap Assets
Assets
9451000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1167000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1359000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6608000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3993000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
100000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
350000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8225000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5352000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
791000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
438000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q4 us-gaap Liabilities
Liabilities
9454000
CY2021Q4 us-gaap Liabilities
Liabilities
5352000
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 dnth Preferred Stock Par Value Per Share
PreferredStockParValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
33336283
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10329266
CY2022Q4 dnth Convertible Preferred Stock
ConvertiblePreferredStock
118024000
CY2021Q4 dnth Convertible Preferred Stock
ConvertiblePreferredStock
21348000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
8722279
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3706968
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
875279
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
875279
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
875279
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
875279
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1661000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
143000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45868000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-17392000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-161000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-44368000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-17249000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
83110000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9451000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6417000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1476000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29379000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12606000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6743000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1956000
CY2022 us-gaap Operating Expenses
OperatingExpenses
36122000
CY2021 us-gaap Operating Expenses
OperatingExpenses
14562000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-29705000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-13086000
CY2022 us-gaap Interest Income Other
InterestIncomeOther
1145000
CY2021 us-gaap Interest Income Other
InterestIncomeOther
3000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
136000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-26000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-52000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1229000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-23000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-28476000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-13109000
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-32.57
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-32.57
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-15.01
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-15.01
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
874234
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
874234
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
873471
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
873471
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-28476000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-13109000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-161000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-161000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28637000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13109000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-4203000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
63000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-13109000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-17249000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1518000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-28476000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-161000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-44368000
CY2022 us-gaap Profit Loss
ProfitLoss
-28476000
CY2021 us-gaap Profit Loss
ProfitLoss
-13109000
CY2022 us-gaap Depreciation
Depreciation
30000
CY2021 us-gaap Depreciation
Depreciation
0
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1518000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
63000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
606000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
117000
CY2022 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
4231000
CY2021 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
469000
CY2022 dnth Unbilled Receivable From Related Party
UnbilledReceivableFromRelatedParty
69000
CY2021 dnth Unbilled Receivable From Related Party
UnbilledReceivableFromRelatedParty
-1007000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
631000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
271000
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
31000
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
30000
CY2022 dnth Accounts Payable Accrued Expenses And Lease Liabilities
AccountsPayableAccruedExpensesAndLeaseLiabilities
2280000
CY2021 dnth Accounts Payable Accrued Expenses And Lease Liabilities
AccountsPayableAccruedExpensesAndLeaseLiabilities
4919000
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
891000
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29070000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9904000
CY2022 us-gaap Payments For Capital Improvements
PaymentsForCapitalImprovements
139000
CY2021 us-gaap Payments For Capital Improvements
PaymentsForCapitalImprovements
33000
CY2022 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
61680000
CY2021 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0
CY2022 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
2000000
CY2021 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
0
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-59819000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-33000
CY2022 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
100000000
CY2022 us-gaap Payments For Repurchase Of Convertible Preferred Stock
PaymentsForRepurchaseOfConvertiblePreferredStock
3324000
CY2021 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
15000000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
88000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
96676000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14912000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7787000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4975000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7638000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2663000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15425000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7638000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15365000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7638000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
60000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
0
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15425000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7638000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
0
CY2021 us-gaap Interest Paid Net
InterestPaidNet
0
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2022 dnth Additions To Right Of Use Lease Assets From New Operating Lease Liabilities
AdditionsToRightOfUseLeaseAssetsFromNewOperatingLeaseLiabilities
931000
CY2021 dnth Additions To Right Of Use Lease Assets From New Operating Lease Liabilities
AdditionsToRightOfUseLeaseAssetsFromNewOperatingLeaseLiabilities
0
CY2023Q2 dnth Proceeds From Pre Closing Financing
ProceedsFromPreClosingFinancing
72000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11021248
CY2023Q3 dnth Split Adjusted Exchange Ratio Of Reverse Merger
SplitAdjustedExchangeRatioOfReverseMerger
0.2181
CY2023Q3 dnth Split Adjusted Exchange Ratio Of Reverse Merger
SplitAdjustedExchangeRatioOfReverseMerger
0.2181
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
273000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4000
CY2022Q4 dnth Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
183000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results may differ materially from those estimates. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates including the following: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Significant estimates are used in the following areas, among others: the recognition of research and development expense, stock-based compensation expense and revenue recognition. </div>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and short-term investments. The Company regularly maintains deposits in accredited financial institutions in excess of federally insured limits. The Company invests its excess cash primarily in money market funds, U.S. treasury securities and U.S. government agency securities in accordance with the Company’s investment policy. The Company’s investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. The Company has not experienced any realized losses related to its cash, cash equivalents and short-term investments and management believes the Company is not exposed to significant risks of losses. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2022, the Company held cash deposits at Silicon Valley Bank (“SVB”) in excess of government insured limits. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation was appointed as receiver. No losses were incurred by the Company on deposits that were held at SVB. Management believes that the Company is not currently exposed to significant credit risk as the vast majority of the Company’s deposits were either owned directly by the Company and held in custody at a third-party financial institution or, subsequent to March 10, 2023, have been transferred to a third-party financial institution. The Company does not currently have any other significant relationships with SVB. </div>
CY2022 us-gaap Revenue Recognition Services Licensing Fees
RevenueRecognitionServicesLicensingFees
<div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">License Revenue—Related Party </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, the Company’s only revenue has been attributable to an upfront payment and cost reimbursements under the Company’s license agreement with Zenas. The Company has not generated any revenue from product sales and does not expect to generate any revenue from product sales for the foreseeable future. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue pursuant to ASC 606,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Revenue from Contracts with Customers </div></div>(“ASC 606”). ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the performance obligation is satisfied. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates the performance obligations promised in a contract that are based on goods and services that will be transferred to the customer and determine whether those obligations are both (i) capable of being distinct and (ii) distinct in the context of the contract. To the extent a contract includes multiple promised goods and services, the Company applies judgment to determine whether promised goods and services are both capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential transaction price and the likelihood that the transaction price will be received. Variable consideration is included in the transaction price if, in management’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. The Company then allocates the transaction price to each performance obligation and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company’s balance sheets. If the related performance obligation is expected to be satisfied within the next twelve months this will be classified in current liabilities. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional information and disclosures required under ASC 606 are included in Note 12. </div>
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
198000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
0
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
4000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
0
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
34000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
17000
CY2022 us-gaap Lease Cost
LeaseCost
236000
CY2021 us-gaap Lease Cost
LeaseCost
17000
CY2021Q4 dnth Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
0
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
60286000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
164000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
60125000
CY2022Q4 dnth Prepaid Materials Supplies And Research And Development Services
PrepaidMaterialsSuppliesAndResearchAndDevelopmentServices
820000
CY2021Q4 dnth Prepaid Materials Supplies And Research And Development Services
PrepaidMaterialsSuppliesAndResearchAndDevelopmentServices
243000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
32000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
21000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
53000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
10000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
905000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
274000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8728
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8767
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
172000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
33000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
30000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
0
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
142000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33000
CY2022 dnth Depreciation Expense
DepreciationExpense
30000
CY2021 dnth Depreciation Expense
DepreciationExpense
0
CY2022Q4 dnth Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
4329000
CY2021Q4 dnth Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
3560000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2084000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
207000
CY2022Q4 dnth Accrued Professional Fees Current And Other
AccruedProfessionalFeesCurrentAndOther
195000
CY2021Q4 dnth Accrued Professional Fees Current And Other
AccruedProfessionalFeesCurrentAndOther
226000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6608000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3993000
CY2022 us-gaap Description Of Lessee Leasing Arrangements Operating Leases
DescriptionOfLesseeLeasingArrangementsOperatingLeases
The Company leases space under operating leases for administrative offices in New York, New York and Waltham, Massachusetts. The Company also leased office space under operating leases, which had a non-cancelable lease term of less than one year and, therefore, management elected the practical expedient to exclude these short-term leases from right-of-use assets and lease liabilities.
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q4 dnth Deferred Tax Assets Organizational Costs
DeferredTaxAssetsOrganizationalCosts
4000
CY2021Q4 dnth Deferred Tax Assets Organizational Costs
DeferredTaxAssetsOrganizationalCosts
5000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
351000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
365000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
188000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
904000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
116000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
788000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
350000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
438000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
788000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P30M
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.103
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
33336283
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10329266
CY2021Q4 dnth Preferred Stock Par Value Per Share
PreferredStockParValuePerShare
0.0001
CY2022Q4 dnth Preferred Stock Par Value Per Share
PreferredStockParValuePerShare
0.0001
CY2022Q4 dnth Common Stock Minimum Issue Price Per Share For Conversion Of Temporary Equity Into Permanent Equity
CommonStockMinimumIssuePricePerShareForConversionOfTemporaryEquityIntoPermanentEquity
8.693
CY2022 dnth Minimum Gross Proceeds From The Issuance Of Common Stock For Conversion Of Temporary Equity Into Permanent Equity
MinimumGrossProceedsFromTheIssuanceOfCommonStockForConversionOfTemporaryEquityIntoPermanentEquity
40000000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0308
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.012
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.31
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
248603
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.92
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
248603
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.92
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y8M12D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
194000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.24
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1031567
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.44
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
6716
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.55
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1273454
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.95
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
621000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
181171
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.18
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y1M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
229000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1092283
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
8.08
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P9Y4M24D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
392000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.24
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.31
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
483000
CY2022Q4 dnth Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
4315000
CY2021Q4 dnth Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
0
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
484000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
57000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1518000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
63000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.022
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.063
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.022
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.025
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.03
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.224
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.297
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
5383000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4651000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1120000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11762000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
5200000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11566000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5194000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
196000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
6000
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
189000
CY2022Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
7000
CY2021Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
6000
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5194000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1307000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
6372000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3887000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11566000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5194000
CY2022 dnth Period Over Which Ownership Change Is Permitted
PeriodOverWhichOwnershipChangeIsPermitted
P3Y
CY2022Q4 dnth Maximum Percentage Change In Ownership Interest Permissible
MaximumPercentageChangeInOwnershipInterestPermissible
0.50
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-28476000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-13109000
CY2022 dnth Weightedaveragecommonsharesoutstanding
Weightedaveragecommonsharesoutstanding
875279
CY2021 dnth Weightedaveragecommonsharesoutstanding
Weightedaveragecommonsharesoutstanding
875279
CY2022 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
1045
CY2021 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
1808
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
874234
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
874234
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
873471
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
873471
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-32.57
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-32.57
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-15.01
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-15.01
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8547949
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2507035

Files In Submission

Name View Source Status
0001193125-23-301206-index-headers.html Edgar Link pending
0001193125-23-301206-index.html Edgar Link pending
0001193125-23-301206.txt Edgar Link pending
0001193125-23-301206-xbrl.zip Edgar Link pending
d639778d8k.htm Edgar Link pending
d639778dex231.htm Edgar Link pending
d639778dex991.htm Edgar Link pending
dnth-20231221.xsd Edgar Link pending
dnth-20231221_cal.xml Edgar Link unprocessable
dnth-20231221_lab.xml Edgar Link unprocessable
dnth-20231221_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
dnth-20231221_pre.xml Edgar Link unprocessable
d639778d8k_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending